November 2016 Member News

Oct 20, 2016

The Hutchinson Clinic welcomes Shannon Haenel, DO, to its staff. Dr. Haenel is an oncologist and hematologist specializing in cancer treatments and blood disorders; she has a special interest in new therapies for lung cancers.

Patrick J. Kiel, PharmD, BCOP, Bryan P. Schneider, MD, and Milan Radovich, PhD, are lead and senior authors of a study conducted at the Indiana University School of Medicine that found that patients with metastatic cancer that had not responded to other treatments had improved outcomes when they received genomic-guided therapy compared to those who did not. The study was published online on July 15 in Oncotarget.

Filipa Lynce, MD, is leading a phase II study at Georgetown Lombardi Comprehensive Cancer Center that will evaluate the safety of palbociclib in African-American patients, including those who may have a low white blood cell count due to benign ethnic neutropenia. 

Pierre Massion, MD, Cornelius Vanderbilt Professor of Medicine, was chosen to direct the Vanderbilt-Ingram Cancer Center Cancer Early Detection and Prevention Initiative. 

Janice M. Mehnert, MD, director of the Phase I/Investigational Therapeutics Program at Rutgers Cancer Institute of New Jersey, is a co-principal investigator on a $2+ millon grant (R01CA193970-01A1) recently awarded by the National Cancer Institute. She is collaborating with researcher Ryan J. Sullivan, MD, of Massachusetts General Hospital Cancer Center, to improve upon available cancer therapies that aim to block specific pathways that promote tumor growth. 

Researchers at NYU Langone Medical Center have identified a new signaling pathway that helps cancer cells cope with the lack of oxygen found inside tumors. Benjamin Gilbert Neel, MD, PhD, director of the Perlmutter Cancer Center, said, “Our results, by yielding a new understanding of cancer cell response to hypoxia, hopefully will enable the design of future treatments that drive such cells into low-oxygen environments and then take away their ability to survive these conditions.”

Charles B. Simone II, MD, has been named the new medical director of the Maryland Proton Treatment Center. He will participate in development of clinical trials and research protocols, assume a leadership role within the Maryland Proton Alliance, and provide expertise in refining criteria for proton therapy patient selection within the department’s clinical practice guidelines.

Mark A. Socinski, MD, a thoracic oncology expert, joined the Florida Hospital Cancer Institute from the University of Pittsburgh Medical Center.

Past ASCO President Sandra M. Swain, MD, FACP, of Georgetown University, was featured in the Washington Business Journal’s “Women Who Mean Business” series. The profile highlights her new role as associate dean of research development at Georgetown.

Melanie Thomas, MD, of Gibbs Cancer Center, and Carolyn Britten, MD, of the Medical University of South Carolina (MUSC), were principal investigators on a phase I study of a first-in-class, orally administered sphingosine kinase-2 selective inhibitor with anticancer and anti-inflammatory activities, for which final results have been announced. The study was conducted at MUSC.

Lois B. Travis, MD, ScD, and Lawrence H. Einhorn, MD, led a multi-institutional study based at Indiana University that analyzed the cumulative effects of cisplatin-based chemotherapy on hearing levels in testicular cancer survivors through comprehensive audiometry measurements. Co-first author Robert D. Frisina, PhD, designed the auditory portion of the study. 

 

In Memoriam

Gregory A. Curt, MD

Janet Cuttner, MD

Robert Westscott Frelick, MD, FACP

Robert B. Livingston, MD

C. Randy Lomax, MA, MFT

Daniel J. Sargent, PhD

Michael Sorell, MD


Advertisement
Back to Top